Menu
Back to Journals » Pediatric Health, Medicine and Therapeutics » Volume 4
Long-term management of Alport syndrome in pediatric patients
Authors Kashtan CE
Received 12 March 2013
Accepted for publication 24 April 2013
Published 4 June 2013 Volume 2013:4 Pages 41—45
DOI https://doi.org/10.2147/PHMT.S35667
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 6
Clifford E Kashtan
Department of Pediatrics, Division of Nephrology, University of Minnesota Medical School, Minneapolis, MN, USA
Abstract: Alport syndrome, an important inherited cause of end-stage renal disease, has long been considered an untreatable disorder. That view is changing as a result of treatment studies in experimental animals and human populations. This review describes current management of Alport kidney disease, which is based on early diagnosis and institution of therapy with antagonists of the renin-angiotensin-aldosterone system.
Keywords: Alport syndrome, glomerular basement membrane, type IV collagen, familial hematuria
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.